ROS1-dependent cancers — biology, diagnostics and therapeutics
Alexander Drilon(Memorial Sloan Kettering Cancer Center), Monika A. Davare(Oregon Health & Science University), Clare Keddy(Oregon Health & Science University), Adam J. Schoenfeld(Memorial Sloan Kettering Cancer Center), Chelsea Jenkins(Oregon Health & Science University), Sudarshan R. Iyer(Oregon Health & Science University)
Cited by 288
Related Papers
Acquired Resistance to Immune Checkpoint Inhibitors
|Cancer Cell|2020|927
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|835
Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers
|New England Journal of Medicine|2020|766
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials
|The Lancet Oncology|2019|537
Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib
|Annals of Oncology|2019|413